文献速递免疫规划慢病防控与筛查卫生政策与健康促进

50岁及以上成人双剂重组带状疱疹疫苗系列完成情况

Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older.
PubMed 文献 · Vaccine · 2021-01-11

研究纳入2018年4-11月接种首剂RZV的Kaiser Permanente南加州≥50岁成员31120人,评估9个月内第二剂完成率及影响因素。67.2%完成系列;调整分析显示完成率与种族/族裔、社区收入和教育、无慢性肺病/糖尿病/痴呆、就诊行为、流感疫苗接种、接种月份及同期接种其他疫苗相关,首剂后全身反应或疼痛与完成无关。

要点

  • RZV系列早期实施完成率67.2%,仍欠理想。
  • 完成率随种族/族裔、社会经济地位、健康状况和就医行为而异。
  • 首剂后全身反应或疼痛未影响系列完成。

核心结论

  • RZV系列在实施早期完成率欠佳,完成情况因种族/族裔、社会经济地位、健康状况和就医行为而异,提示需针对改进。

研究设计与样本

  • 回顾性队列研究,纳入Kaiser Permanente南加州≥50岁成员31120名于2018年4-11月接种首剂RZV者,要求首剂前12个月至首剂后9个月连续参保。
  • 完成定义为首剂后≥4周至9个月内接种第二剂(允许3个月宽限期)。
  • 采用多变量logistic回归估计与完成相关的调整比值比及95%置信区间。

主要发现

  • 31120名首剂接种者中,67.2%在9个月内完成系列。
  • 调整分析中,完成率较高与以下因素相关:白人较黑人/西班牙裔、较高社区收入和教育、无慢性肺病/糖尿病/痴呆、首剂前后更多门诊就诊和更少急诊就诊、首剂后无住院、接种流感疫苗、首剂在2018年6-11月而非4-5月接种、首剂未同期接种其他疫苗。
  • 首剂后全身反应或疼痛与完成无关。

临床怎么用

  • 在接种首剂RZV时识别完成率较低的人群(少数族裔、低社会经济地位、有慢性肺病/糖尿病/痴呆、急诊就诊多或首剂后住院者),针对性提醒和随访以促进第二剂接种。

局限性

  • 研究为观察性设计,仅反映早期实施阶段单一医疗系统的情况,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2017, a new adjuvanted recombinant zoster vaccine (RZV) was recommended for adults ≥50 years as two-dose series 2-6 months apart. We evaluated two-dose RZV completion and factors associated with completion. METHODS: The study included Kaiser Permanente Southern California members ≥50 years who received an RZV dose during April-November 2018 and had continuous membership 12 months before to 9 months after the first RZV dose. Completion was defined as receipt of the second dose ≥4 weeks to 9 months after the first dose (allowing 3-month grace period). Characteristics including age, sex, race/ethnicity, Medicaid status, neighborhood level income and education, comorbidities, history of zoster, health care utilization before and after the first dose, receipt of influenza vaccine, vaccination month (supply shortage proxy), concomitant vaccine, medical center, and medically attended reactions, pain, or gout after the first dose were compared between completers and non-completers. Adjusted odds ratios and 95% confidence intervals for factors associated with completion were estimated by multivariable logistic regression. RESULTS: Among 31,120 first dose recipients, 67.2% completed the series within 9 months. In adjusted analyses, higher completion was associated with White compared with Black or Hispanic race/ethnicity, higher neighborhood income and education, no chronic pulmonary disease, diabetes, or dementia, more outpatient visits and fewer emergency department visits before or after the first dose, no hospitalizations after the first dose, receipt of influenza vaccine, receipt of the first dose in June-November rather than April-May 2018, and no concomitant vaccine with the first dose. Systemic reactions or pain after the first dose was not associated with completion. CONCLUSION: Completion of RZV series appears suboptimal in the early phase of implementation. Despite similar accessibility in a health care system, completion varied by race/ethnicity, socioeconomic status, health status, and care seeking behavior, suggesting areas to target for improvement.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ackerson B, Qian L, Sy LS, et al. Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older. Vaccine. 2021. PMID: 33441234. doi:10.1016/j.vaccine.2020.12.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。